SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 3rd, 2023 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2023, and is between Adamis Pharmaceuticals Corporation, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Adamis Pharmaceuticals Corporation 8-KAdamis Pharmaceuticals Corp • August 3rd, 2023 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) to certain purchasers (the “Purchasers”) of up to an aggregate of (i) 4,800,000 common units (each a “Common Unit” and collectively, the “Common Units”), with each Common Unit consisting of (A) one share (each a “Share” and collectively, the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (B) one common stock purchase warrant (each a “Warrant” and collectively, the “Warrants”) to purchase one share of Common Stock (the “Warrant Shares”) exercisable immediately and expiring five years after the date of issuance at an exercise price of $1.35 per share of Common Stock, and (ii) 1,130,
